Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib.

Facchinetti F, Gnetti L, Balestra V, Silva M, Silini EM, Ventura L, Majori M, Bordi P, Tiseo M.

Invest New Drugs. 2018 Aug 1. doi: 10.1007/s10637-018-0652-3. [Epub ahead of print]

PMID:
30066208
2.

Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non-Small-cell Lung Cancer: Clinical and Budget Effect.

Paolini D, Tiseo M, Demma F, Furneri G, Dionisi M, Akkermans M, Marchetti A.

Clin Lung Cancer. 2018 May 31. pii: S1525-7304(18)30132-3. doi: 10.1016/j.cllc.2018.05.012. [Epub ahead of print]

3.

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab.

Facchinetti F, Veneziani M, Buti S, Gelsomino F, Squadrilli A, Bordi P, Bersanelli M, Cosenza A, Ferri L, Rapacchi E, Mazzaschi G, Leonardi F, Quaini F, Ardizzoni A, Missale G, Tiseo M.

Immunotherapy. 2018 Jun;10(8):681-694. doi: 10.2217/imt-2017-0175.

PMID:
29882691
4.

Is the door open to further investigation with antiangiogenesis in SCLC?

Tiseo M, Boni L, Ardizzoni A.

J Thorac Dis. 2018 Apr;10(Suppl 9):S1127-S1128. doi: 10.21037/jtd.2018.03.87. No abstract available.

5.

Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.

Facchinetti F, Gnetti L, Caruana P, Fornaroli F, Luigi de'Angelis G, Sabato M, Ferri L, Cosenza A, Bordi P, Tiseo M.

Clin Lung Cancer. 2018 May 5. pii: S1525-7304(18)30095-0. doi: 10.1016/j.cllc.2018.04.013. [Epub ahead of print] No abstract available.

PMID:
29801705
6.

No room for statins in the quest for survival benefits in small cell lung cancer.

Facchinetti F, Tiseo M.

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S131-S133. doi: 10.21037/tlcr.2018.03.07. No abstract available.

7.

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.

Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN.

J Clin Oncol. 2018 May 16:JCO2017775841. doi: 10.1200/JCO.2017.77.5841. [Epub ahead of print]

PMID:
29768119
8.

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.

Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O'Brien M.

Lancet Oncol. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1. Epub 2018 May 9.

PMID:
29753703
9.

L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib.

Callegari D, Ranaghan KE, Woods CJ, Minari R, Tiseo M, Mor M, Mulholland AJ, Lodola A.

Chem Sci. 2018 Feb 12;9(10):2740-2749. doi: 10.1039/c7sc04761d. eCollection 2018 Mar 14.

10.

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.

Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, Tiseo M, Planchard D.

Cancer Treat Rev. 2018 May;66:82-94. doi: 10.1016/j.ctrv.2018.04.006. Epub 2018 Apr 24. Review.

PMID:
29729495
11.

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.

Minari R, Bordi P, La Monica S, Squadrilli A, Leonetti A, Bottarelli L, Azzoni C, Lagrasta CAM, Gnetti L, Campanini N, Petronini PG, Alfieri R, Tiseo M.

J Thorac Oncol. 2018 Jun;13(6):e89-e91. doi: 10.1016/j.jtho.2018.03.013. Epub 2018 Mar 27. No abstract available.

PMID:
29596911
12.

Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study.

Cortellini A, Bersanelli M, Buti S, Gambale E, Atzori F, Zoratto F, Parisi A, Brocco D, Pireddu A, Cannita K, Iacono D, Migliorino MR, Gamucci T, De Tursi M, Sidoni T, Tiseo M, Michiara M, Papa A, Angius G, Tomao S, Fargnoli MC, Natoli C, Ficorella C.

Immunotherapy. 2018 Jun;10(8):643-655. doi: 10.2217/imt-2017-0167. Epub 2018 Mar 22.

13.

ALK-positive adenocarcinoma of the lung expressing neuroendocrine markers and presenting as a "pituitary adenoma".

Mengoli MC, Bertolini F, Maur M, Barbieri F, Longo L, Gasparri P, Tiseo M, Rossi G.

Pathologica. 2017 Dec;109(4):408-411.

PMID:
29449735
14.

Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH: A Clinicopathologic, Radiologic, and Immunomolecular Comparison Study.

Mengoli MC, Rossi G, Cavazza A, Franco R, Marino FZ, Migaldi M, Gnetti L, Silini EM, Ampollini L, Tiseo M, Lococo F, Fournel L, Spagnolo P, Cottin V, Colby TV.

Am J Surg Pathol. 2018 May;42(5):646-655. doi: 10.1097/PAS.0000000000001033.

PMID:
29438170
15.

Enteral administration of TKIs: report of a response to ceritinib in an ALK-positive NSCLC patient and literature review.

Facchinetti F, Bordi P, Bini P, Bidin L, Camisa R, Tiseo M.

Curr Drug Targets. 2018 Feb 12. doi: 10.2174/1389450119666180213102939. [Epub ahead of print]

PMID:
29437006
16.

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.

Minari R, Bordi P, Del Re M, Facchinetti F, Mazzoni F, Barbieri F, Camerini A, Comin CE, Gnetti L, Azzoni C, Nizzoli R, Bortesi B, Rofi E, Petreni P, Campanini N, Rossi G, Danesi R, Tiseo M.

Lung Cancer. 2018 Jan;115:21-27. doi: 10.1016/j.lungcan.2017.11.011. Epub 2017 Nov 13.

PMID:
29290257
17.

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.

Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M, Caruso M, Simonelli M, Perrino M, De Vincenzo F, Toffalorio F, Damiano V, Pasello G, Garbella E, Ali M, Conforti F, Ottaviano M, Cioffi A, De Placido S, Giordano L, Bertossi M, Destro A, Di Tommaso L, Santoro A.

J Clin Oncol. 2018 Feb 1;36(4):342-349. doi: 10.1200/JCO.2017.74.4078. Epub 2017 Dec 14.

PMID:
29240542
18.

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.

La Monica S, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Digiacomo G, Flammini L, Barocelli E, Minari R, Naldi N, Petronini PG, Tiseo M, Alfieri R.

J Exp Clin Cancer Res. 2017 Dec 4;36(1):174. doi: 10.1186/s13046-017-0653-7.

19.

Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.

Fumarola C, Cretella D, La Monica S, Bonelli MA, Alfieri R, Caffarra C, Quaini F, Madeddu D, Falco A, Cavazzoni A, Digiacomo G, Mazzaschi G, Vivo V, Barocelli E, Tiseo M, Petronini PG, Ardizzoni A.

Oncotarget. 2017 Jul 17;8(54):91841-91859. doi: 10.18632/oncotarget.19279. eCollection 2017 Nov 3.

20.

Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.

Pellegrino B, Facchinetti F, Bordi P, Silva M, Gnetti L, Tiseo M.

Clin Lung Cancer. 2018 Mar;19(2):e151-e161. doi: 10.1016/j.cllc.2017.10.008. Epub 2017 Oct 28. Review.

PMID:
29174221
21.

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.

Del Re M, Bordi P, Petrini I, Rofi E, Mazzoni F, Belluomini L, Vasile E, Restante G, Di Costanzo F, Falcone A, Frassoldati A, van Schaik RHN, Steendam CMJ, Chella A, Tiseo M, Morganti R, Danesi R.

Oncotarget. 2017 Sep 15;8(49):86056-86065. doi: 10.18632/oncotarget.20947. eCollection 2017 Oct 17.

22.

Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value.

Mazzaschi G, Madeddu D, Falco A, Bocchialini G, Goldoni M, Sogni F, Armani G, Lagrasta CA, Lorusso B, Mangiaracina C, Vilella R, Frati C, Alfieri R, Ampollini L, Veneziani M, Silini EM, Ardizzoni A, Urbanek K, Aversa F, Quaini F, Tiseo M.

Clin Cancer Res. 2018 Jan 15;24(2):407-419. doi: 10.1158/1078-0432.CCR-17-2156. Epub 2017 Oct 26.

PMID:
29074606
23.

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.

Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C, Léna H, Berruti A, Damiano V, Buikhuisen W, Grønbæk H, Lombard-Bohas C, Grohé C, Minotti V, Tiseo M, De Castro J, Reed N, Gislimberti G, Singh N, Stankovic M, Öberg K, Baudin E.

Lancet Oncol. 2017 Dec;18(12):1652-1664. doi: 10.1016/S1470-2045(17)30681-2. Epub 2017 Oct 23.

PMID:
29074099
24.

Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN.

Cavazzoni A, La Monica S, Alfieri R, Ravelli A, Van Der Steen N, Sciarrillo R, Madeddu D, Lagrasta CAM, Quaini F, Bonelli M, Fumarola C, Cretella D, Digiacomo G, Tiseo M, Peters GJ, Ardizzoni A, Petronini PG, Giovannetti E.

Oncotarget. 2017 May 23;8(32):53068-53083. doi: 10.18632/oncotarget.18087. eCollection 2017 Aug 8.

25.

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.

Gobbini E, Galetta D, Tiseo M, Graziano P, Rossi A, Bria E, Di Maio M, Rossi G, Gregorc V, Riccardi F, Scotti V, Ceribelli A, Buffoni L, Delmonte A, Franchina T, Migliorino MR, Cortinovis D, Pisconti S, Bordi P, Catino A, Maiello E, Arizio F, Novello S; other Co-Authors.

Lung Cancer. 2017 Sep;111:30-37. doi: 10.1016/j.lungcan.2017.06.009. Epub 2017 Jun 16.

PMID:
28838394
26.

MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study.

Mozzoni P, Ampollini L, Goldoni M, Alinovi R, Tiseo M, Gnetti L, Carbognani P, Rusca M, Mutti A, Percesepe A, Corradi M.

Dis Markers. 2017;2017:9645940. doi: 10.1155/2017/9645940. Epub 2017 Jul 3.

27.

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives.

Rossi G, Jocollé G, Conti A, Tiseo M, Zito Marino F, Donati G, Franco R, Bono F, Barbisan F, Facchinetti F.

Lung Cancer (Auckl). 2017 Jul 7;8:45-55. doi: 10.2147/LCTT.S120172. eCollection 2017. Review.

28.

Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.

Proto C, Lo Russo G, Corrao G, Ganzinelli M, Facchinetti F, Minari R, Tiseo M, Garassino MC.

Tumori. 2017 Jul 31;103(4):325-337. doi: 10.5301/tj.5000663. Epub 2017 Jul 1. Review.

PMID:
28708233
29.

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.

Bonelli MA, Digiacomo G, Fumarola C, Alfieri R, Quaini F, Falco A, Madeddu D, La Monica S, Cretella D, Ravelli A, Ulivi P, Tebaldi M, Calistri D, Delmonte A, Ampollini L, Carbognani P, Tiseo M, Cavazzoni A, Petronini PG.

Neoplasia. 2017 Aug;19(8):637-648. doi: 10.1016/j.neo.2017.05.003. Epub 2017 Jul 11.

30.

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.

Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Spitaleri G, Bria E, Novello S.

Clin Lung Cancer. 2018 Jan;19(1):93-104. doi: 10.1016/j.cllc.2017.05.016. Epub 2017 Jun 1.

PMID:
28645631
31.

Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.

Bordi P, Tiseo M, Rofi E, Petrini I, Restante G, Danesi R, Del Re M.

Clin Lung Cancer. 2017 Nov;18(6):692-697. doi: 10.1016/j.cllc.2017.04.013. Epub 2017 May 18.

PMID:
28601386
32.

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodríguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR.

J Clin Oncol. 2017 Aug 1;35(22):2490-2498. doi: 10.1200/JCO.2016.71.5904. Epub 2017 May 5.

PMID:
28475456
33.

Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.

Pellegrino B, Musolino A, Tiseo M.

Ann Oncol. 2017 Jun 1;28(6):1405-1406. doi: 10.1093/annonc/mdx126. No abstract available.

PMID:
28383638
34.

Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.

Facchinetti F, Rossi G, Bria E, Soria JC, Besse B, Minari R, Friboulet L, Tiseo M.

Cancer Treat Rev. 2017 Apr;55:83-95. doi: 10.1016/j.ctrv.2017.02.010. Epub 2017 Mar 12. Review.

PMID:
28342334
35.

Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.

Facchinetti F, Proto C, Minari R, Garassino M, Tiseo M.

Handb Exp Pharmacol. 2017 Mar 23. doi: 10.1007/164_2017_16. [Epub ahead of print]

PMID:
28332047
36.

Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM).

Di Maio M, Bruzzi P, Perrone F, Torri V, Montemurro F, Tiseo M, Vasile E.

ESMO Open. 2016 Dec 12;1(6):e000109. doi: 10.1136/esmoopen-2016-000109. eCollection 2016. Review.

37.

Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).

Tiseo M, Damato A, Longo L, Barbieri F, Bertolini F, Stefani A, Migaldi M, Gnetti L, Camisa R, Bordi P, Buti S, Rossi G.

Lung Cancer. 2017 Feb;104:24-30. doi: 10.1016/j.lungcan.2016.12.005. Epub 2016 Dec 14.

PMID:
28212996
38.
39.

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.

Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, Brighenti M, Zanelli F, Defraia E, Chiari R, Dazzi C, Tibaldi C, Turolla GM, D'Alessandro V, Zilembo N, Trolese AR, Grossi F, Riccardi F, Ardizzoni A.

J Clin Oncol. 2017 Apr 20;35(12):1281-1287. doi: 10.1200/JCO.2016.69.4844. Epub 2017 Jan 30.

PMID:
28135143
40.

Extra-pleuric coaxial system for CT-guided percutaneous fine-needle aspiration biopsy (FNAB) of small (≤20 mm) lung nodules: a novel technique using multiplanar reconstruction (MPR) images.

Capasso R, Nizzoli R, Tiseo M, Pedrazzi G, Brunese L, Rotondo A, De Filippo M.

Med Oncol. 2017 Feb;34(2):17. doi: 10.1007/s12032-016-0871-4. Epub 2016 Dec 29.

PMID:
28035579
41.

'Turban-like' skull metastasis from pulmonary adenocarcinoma.

Mengoli MC, Rossi G, Tiseo M, Barbieri F, Pifferi M, Bertolini F, Lococo F.

Thorax. 2017 Aug;72(8):767-768. doi: 10.1136/thoraxjnl-2016-209409. Epub 2016 Dec 2. No abstract available.

PMID:
27913767
42.

Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.

Bersanelli M, Bini P, Rabaiotti E, Facchinetti F, De Filippo M, Bortesi B, Buti S, Tiseo M.

Tumori. 2017 Jan 21;103(1):66-71. doi: 10.5301/tj.5000423. Epub 2015 Sep 19.

PMID:
26391764
43.

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.

Facchinetti F, Marabelle A, Rossi G, Soria JC, Besse B, Tiseo M.

J Thorac Oncol. 2016 Nov;11(11):1819-1836. doi: 10.1016/j.jtho.2016.05.027. Epub 2016 Jun 8. Review.

44.

Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC.

Ardizzoni A, Tiseo M, Boni L, Di Maio M, Buffoni L, Belvedere O, Grossi F, D'Alessandro V, de Marinis F, Barbera S, Caroti C, Favaretto A, Cortinovis D, Morrica B, Tixi L, Ceschia T, Parisi S, Ricardi U, Grimaldi A, Loreggian L, Navarria P, Huber RM, Belani C, Brunsvig PF, Scagliotti GV, Scolaro T.

Lung Cancer. 2016 Oct;100:30-37. doi: 10.1016/j.lungcan.2016.07.026. Epub 2016 Jul 27.

45.

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

Cappuzzo F, Morabito A, Normanno N, Bidoli P, Del Conte A, Giannetta L, Montanino A, Mazzoni F, Buosi R, Burgio MA, Cerea G, Chiari R, Cortinovis D, Finocchiaro G, Foltran L, Migliorino MR, Tiseo M, Ferrari S, De Marinis F.

Lung Cancer. 2016 Sep;99:31-7. doi: 10.1016/j.lungcan.2016.06.008. Epub 2016 Jun 14.

PMID:
27565910
46.
47.

MET DNA Alterations in NSCLC-Letter.

Mengoli MC, Bertolini F, Tiseo M, Barbieri F, Fiorentino M, Ardizzoni A, Rossi G.

Clin Cancer Res. 2016 Jul 15;22(14):3697-8. doi: 10.1158/1078-0432.CCR-16-0351. No abstract available.

48.

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.

Facchinetti F, Tiseo M, Di Maio M, Graziano P, Bria E, Rossi G, Novello S.

Transl Lung Cancer Res. 2016 Jun;5(3):301-21. doi: 10.21037/tlcr.2016.06.10. Review.

49.

The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.

Novello S, Pinto C, Torri V, Porcu L, Di Maio M, Tiseo M, Ceresoli G, Magnani C, Silvestri S, Veltri A, Papotti M, Rossi G, Ricardi U, Trodella L, Rea F, Facciolo F, Granieri A, Zagonel V, Scagliotti G.

Crit Rev Oncol Hematol. 2016 Aug;104:9-20. doi: 10.1016/j.critrevonc.2016.05.004. Epub 2016 May 13.

PMID:
27286698
50.

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.

Bersanelli M, Minari R, Bordi P, Gnetti L, Bozzetti C, Squadrilli A, Lagrasta CA, Bottarelli L, Osipova G, Capelletto E, Mor M, Tiseo M.

J Thorac Oncol. 2016 Oct;11(10):e121-3. doi: 10.1016/j.jtho.2016.05.019. Epub 2016 May 31. No abstract available.

Supplemental Content

Support Center